Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance [Hematologic Malignancies]

Posted by rob on July 29, 2009 under Uncategorized | Comments are off for this article

Conclusion
Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy. (Source: Journal of Clinical Oncology)